Phaseline

Targets › CBS

CBS (Cystathionine beta-synthase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Jul 2027.

Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine. (UniProt, P35520)

Open in Phaseline: the race on CBS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Travere TherapeuticsPegtibatinase
PEG-modified cystathionine beta-synthase (CBS) enzyme replacement
CBSPhase 3HomocystinuriaJul 2027

Conditions

Homocystinuria (2)

Modalities

protein or peptide (1)

Companies

Travere Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.